CDNA

NEUTRALAnalyst

CareDx, Inc.

2026-09-25

Price

$63.68

+3.76%

This is the 2026-09-25 snapshot — the signals and analysis for CDNA as of this single trading day.

View full CDNA research hub →

Score2.2Noise

Signals3/8 DNA0/13 Act · 2/4 Risk

SentimentNEUTRALScore: 8

Volume1.9xvs 20d avg

Analysis

CareDx (CDNA) is surging due to a BTIG price target upgrade to $74, which cited recent Medicare reimbursement wins and strong transplant diagnostics growth. This fundamental catalyst perfectly aligns with the stock's 'Perfect Stack' and 'Market Leader' technical signals, triggering urgent institutional participation at 1.9x average volume. Operating in a pristine RISK_ON macro regime characterized by tight credit spreads and abundant liquidity, the market is aggressively rewarding this high-conviction price discovery without systemic headwinds.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKWEAK FINISHEXTENSION

Key Takeaways

ACTIONABLE THESIS: BTIG's $74 price target hike and recent Medicare reimbursement wins validate the stock's multi-year breakout and strong relative strength (+21.4% vs SPY).
KEY RISK: The company's uneven profitability record and high operating costs could weigh on the stock if test volumes or reimbursement rates face unexpected pressure.
WHAT TO WATCH: Monitor the $48.97 support level to ensure the breakout holds, alongside any regulatory updates regarding Medicare billing for transplant diagnostics.

← Back to 2026-09-25 View Full CDNA History →Yahoo Finance &nearr;